investora2z Sunday, 11/24/13 06:32:22 AM Re: None Post # of 773 The stock has been moving up quietly over the last one week. It may make a stronger move after the update on the trials is announced early next month. Senesco's platform technology has a lot of potential, and the trial results so far have confirmed that the possibilities are tremendous. This is especially true if one considers the huge market for cancer drugs. Factor 5A can regulate programmed cell death and cell survival through controlling the expression of pro and anti-apoptotic proteins. The initial use of the technology was to extend shelf life of food and increase crop yield, but the inverse activation of Factor 5A also had huge possibilities for the treatment of cancer. The main drug candidate SNS01T targets B-cell cancers by selectively inducing programmed cell death (apoptosis) using Factor 5A. Cancer therapy trials focus on multiple myeloma and other B-cell cancers. SNS01T has been found to inhibit the growth and even shrink tumors of human B-cell cancers in animal models. SNS01T has an orphan drug status granted by USFDA. The company has numerous patents related to Factor 5A platform. The use in agricultural biotechnology and biofuels development also holds a lot of promise. It has collaborations with big companies like Bayer Crop Science and Monsanto to name a few. In addition to increasing seed yield and plant size, the technology can provide resistance against premature cell death caused by environmental stresses like frost, drought, heat, and soil salinity. According to the arrangements, Senesco is entitled to earn R&D milestones and royalties if their technology is used by the partners. Even the last 10Q contained a milestone payment of $100K. However, the trials and approval will take time and will require funding. The cancer treatment related trials & approvals may take a couple of years. Meanwhile, the agricultural licensing revenues can provide some cash flow, but the company will require external funding from time to time to pursue its research.